<unk>  is not a single disease but encompasses many different pathological processes. Hence treatment is different for each disease. If a specific occupational exposure cause is found, the person should avoid that environment. If a drug cause is suspected, that drug should be discontinued. Many cases due to unknown or connective tissue-based causes are treated with corticosteroids, such as prednisolone. Some people respond to immunosuppressant treatment. Oxygen therapy at home is recommended in those with significantly low oxygen levels. Pulmonary rehabilitation appears to be useful with the benefits being sustainable longer term with improvement in exercise capacity, dyspnoea, and quality of life.<unk>  transplantation is an option if the<unk>  progresses despite therapy in appropriately selected patients with no other contraindications. On October 16, 2014, the Food and Drug Administration approved a new drug for the treatment of Idiopathic Pulmonary Fibrosis (IPF). This drug, Ofev (nintedanib), is marketed by Boehringer Ingelheim Pharmaceuticals, Inc. This drug has been shown to slow the decline of<unk>  function although the drug has not been shown to reduce mortality or improve<unk>  function. The estimated cost of the drug per year is approximately $94,000.
Interstitial lung disease
Idiopathic pulmonary fibrosis
Alveolar lung disease
Alcoholic lung disease
Pulmonary interstitial emphysema
Pulmonary alveolar proteinosis
Pulmonary fibrosis
Emphysema